dm+d

Unassigned

New Medicines

Anticoagulation

Information

New molecular entity
Espero BioPharma
Armetheon

Development and Regulatory status

None
None
Phase III Clinical Trials
Yes

Category

Selective vitamin K epoxide reductase (VKOR) enzyme inhibitor - like warfarin
The prevalence of AF is about 1,600 per 100,000 people. Over 57% are at moderate to high risk of stroke and should be offered anticoagulation therapy. NICE estimate less than half of those with AF who need anticoagulation therapy are currently receiving it [6]. Almost 5,000 aortic valve replacements were carried out on the NHS in England between April 2011 and April 2012 [7].
Anticoagulation
Oral

Evidence based evaluations